{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T17:53:07Z","timestamp":1790963587159,"version":"4.1.0"},"reference-count":34,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2019,11,6]],"date-time":"2019-11-06T00:00:00Z","timestamp":1572998400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2020,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>This phase 1b\/2, multicenter, open\u2010label study evaluated ibrutinib plus durvalumab in relapsed\/refractory follicular lymphoma (FL) or diffuse large B\u2010cell lymphoma (DLBCL). Patients were treated with once\u2010daily ibrutinib 560\u2009mg plus durvalumab 10 mg\/kg every 2\u2009weeks in 28\u2010day\u2009cycles in phase 1b without dose\u2010limiting toxicities, confirming the phase 2 dosing. Sixty\u2010one patients with FL (n = 27), germinal center B\u2010cell (GCB) DLBCL (n = 16), non\u2010GCB DLBCL (n = 16), and unspecified DLBCL (n = 2) were treated. Overall response rate (ORR) was 25% in all patients, 26% in patients with FL, 13% in patients with GCB DLBCL, and 38% in patients with non\u2010GCB DLBCL. Overall, median progression\u2010free survival was 4.6 months and median overall survival was 18.1 months; both were longer in patients with FL than in patients with DLBCL. The most frequent treatment\u2010emergent adverse events (AEs) in patients with FL and DLBCL, respectively, were diarrhea (16 [59%]; 16 [47%]), fatigue (12 [44%]; 16 [47%]), nausea (9 [33%]; 12 [35%]), peripheral edema (7 [26%]; 13 [38%]), decreased appetite (8 [30%]; 11 [32%]), neutropenia (6 [22%]; 11 [32%]), and vomiting (5 [19%]; 12 [35%]). Investigator\u2010defined immune\u2010related AEs were reported in 12\/61 (20%) patients. Correlative analyses were conducted but did not identify any conclusive biomarkers of response. In FL, GCB DLBCL, and non\u2010GCB DLBCL, ibrutinib plus durvalumab demonstrated similar activity to single\u2010agent ibrutinib with the added toxicity of the PD\u2010L1 blockade; the combination resulted in a safety profile generally consistent with those known for each individual agent.<\/jats:p>","DOI":"10.1002\/ajh.25659","type":"journal-article","created":{"date-parts":[[2019,10,17]],"date-time":"2019-10-17T07:15:57Z","timestamp":1571296557000},"page":"18-27","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":56,"title":["Safety and activity of ibrutinib in combination with durvalumab in patients with relapsed or refractory follicular lymphoma or diffuse large B\u2010cell lymphoma"],"prefix":"10.1002","volume":"95","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9665-7415","authenticated-orcid":false,"given":"Alex F.","family":"Herrera","sequence":"first","affiliation":[{"name":"Department of Hematology\/Hematopoietic Cell Transplantation City of Hope National Medical Center  Duarte California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre","family":"Goy","sequence":"additional","affiliation":[{"name":"John Theurer Cancer Center Division of Lymphoma Hackensack University Medical Center  Hackensack New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amitkumar","family":"Mehta","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology University of Alabama  Birmingham Alabama"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radhakrishnan","family":"Ramchandren","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology Karmanos Cancer Institute  Detroit Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M.","family":"Pagel","sequence":"additional","affiliation":[{"name":"Center for Blood Disorders and Stem Cell Transplantation, Division of Oncology Swedish Cancer Institute  Seattle Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakub","family":"Svoboda","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology and Oncology University of Pennsylvania  Philadelphia Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanhong","family":"Guan","sequence":"additional","affiliation":[{"name":"Department of Biostatistics Pharmacyclics LLC, an AbbVie Company  Sunnyvale California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John S.","family":"Hill","sequence":"additional","affiliation":[{"name":"Department of Translational Medicine Pharmacyclics LLC, an AbbVie Company  Sunnyvale California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Kwei","sequence":"additional","affiliation":[{"name":"Department of Translational Medicine Pharmacyclics LLC, an AbbVie Company  Sunnyvale California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily A.","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Clinical Science Pharmacyclics LLC, an AbbVie Company  Sunnyvale California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tycel","family":"Phillips","sequence":"additional","affiliation":[{"name":"Rogel Cancer Center, Division of Hematology and Oncology University of Michigan  Ann Arbor Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,11,6]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2012.12.009"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv304"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-13150-4_8"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw400"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-03-769620"},{"key":"e_1_2_8_7_1","unstructured":"IMBRUVICA (Ibrutinib) [Prescribing Information].Pharmacyclics LLC:Sunnyvale CA;2019."},{"key":"e_1_2_8_8_1","unstructured":"IMBRUVICA (Ibrutinib) [Summary of Product Characteristics].Janssen\u2010Cilag International NV:Beerse Belgium;2018."},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-06-507947"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.76.8853"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-09-804641"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-05-786988"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.2010.00923.x"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3239"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-2660"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-0855"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-02-629600"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-08-3376"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.18.0513"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-04-421826"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2015.02.007"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.48.3685"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70551-5"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.65.9789"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.00766"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1500712112"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.8800"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1097\/PAI.0000000000000408"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501824"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(89)90015-9"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V126.23.1737.1737"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature21349"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.2955.2955"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3884"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(18)30217-5"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fajh.25659","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.25659","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ajh.25659","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.25659","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T10:53:27Z","timestamp":1694170407000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.25659"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,6]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["10.1002\/ajh.25659"],"URL":"https:\/\/doi.org\/10.1002\/ajh.25659","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,6]]},"assertion":[{"value":"2019-06-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-10-11","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-11-06","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}